Compare Amylx Pharmaceuticals Inc (AMLX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Verisign, Inc. trades at $270.69 (market cap $24.58B). The key difference: Verisign, Inc. is far larger — about 12.4× Amylx Pharmaceuticals Inc's market cap, and Verisign, Inc. pays a 1.2% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | VRSN | |
|---|---|---|
Market Cap | $1.98B | $24.58B |
Sector | Health | Technology |
52-Week High | $18.70 | $310.00 |
52-Week Low | $7.64 | $211.49 |
Enterprise Value | $1.70B | $25.82B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
VeriSign (VRSN) trades at $270.11, up 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.67. The company reported Q1 2026 EPS of $2.34, beating expectations, and maintains strong profitability with a net income margin near 50%. Recent news highlights AI-driven domain registration growth and the upcoming Q2 2026 earnings report on July 23, 2026.
The outlook for VRSN is positive, supported by stable revenue growth, high margins, and analyst optimism, but risks include AI disruption to its domain business, contract renewals, and a high debt load. The stock offers potential upside to the consensus target, though investors should monitor earnings execution and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
